← Back to Clinical Trials
Recruiting NCT07241663

NCT07241663 Surgery for Locally Unresectable Pancreatic Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07241663
Status Recruiting
Phase
Sponsor Azienda Ospedaliera di Padova
Condition Locally Advanced Pancreatic Adenocarcinoma
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2025-01-01
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Questionnaire

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2025-01-01 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Pancreatic cancer is a severe disease often diagnosed at an advanced stage, when surgery is not possible. New chemotherapy treatments can sometimes shrink the tumor and make surgery an option. This study aims to understand if surgery after such treatments can improve survival and quality of life in selected patients treated at expert centers.

Eligibility Criteria

Inclusion Criteria: * Patients older than 18 years * Patients able to give informed consent * Histologically confirmed pancreatic adenocarcinoma * LAPC stage according to NCCN10 at diagnosis (Figure 1) * Received at least 4 months of induction chemotherapy * RECIST 1.1 stable disease (SD) or partial response (PR) after induction therapy * Patient considered eligible for radical resection by local MDT Exclusion Criteria: * Informed consent withdrawal * Presence of tumor characteristics precluding surgery * Presence of patient significant comorbidities precluding surgery * Unavailable pre-induction therapy abdominal imaging * Pathological confirmation of any tumor different from PDAC

Frequently Asked Questions

Who can join the NCT07241663 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Locally Advanced Pancreatic Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07241663 currently recruiting?

Yes, NCT07241663 is actively recruiting participants. Visit ClinicalTrials.gov or contact Azienda Ospedaliera di Padova to inquire about joining.

Where is the NCT07241663 trial being conducted?

This trial is being conducted at Padova, Italy.

Who is sponsoring the NCT07241663 clinical trial?

NCT07241663 is sponsored by Azienda Ospedaliera di Padova. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology